Trials / Withdrawn
WithdrawnNCT01090570
Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving Methotrexate
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Plexxikon · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
PLX3397 is a selective inhibitor of Fms and Kit activity. The objective of this study is to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interaction (DDI) of orally administered PLX3397 during 2 weeks of dosing in patients with rheumatoid arthritis (RA) who are on maintenance methotrexate. This study is planned to provide data to inform dose selection for a subsequent 12 week dose ranging study in RA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX3397 | Once-daily oral capsules |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-12-01
- First posted
- 2010-03-22
- Last updated
- 2015-03-17
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01090570. Inclusion in this directory is not an endorsement.